Surfside, Fla. – Pablo Langesfeld, a local man diagnosed with stage‑four pancreatic cancer, is once again confronting Oscar Insurance Company in court. Earlier this year, Judge Migna Sanchez‑Llorens ruled that Oscar must cover the expensive combination drug therapy Avmapki‑Fakzynja, which costs $48,500 every three weeks.
Despite that decision, Oscar’s attorneys returned to the courtroom today, asking the same judge to reverse her own ruling. They argue that Langesfeld never actually received the medication, presenting this as newly‑discovered evidence that could justify a different outcome.
Family and legal team press for relief
“They’re still unwilling to just let go of this, to leave my client in peace,” said Todd Legon, Langesfeld’s attorney. Martin Langesfeld, Pablo’s son, attended the hearing in place of his ailing father. “His own oncologist still thinks this medication is medically necessary, so I don’t see why we’re still here fighting in court,” he said.
The family maintains that Oscar delayed the drug for months, prompting doctors to enroll Pablo in an experimental trial. “They had to change treatment because, as this doctor said, if they didn’t, he would be dead by now,” Martin added.
Medical necessity and next steps
The oncologist testified that Pablo may still need the combination therapy depending on the trial’s results. The judge has not set a new ruling date, but expects a decision within four to five weeks.
Oscar’s attorneys declined to comment after the hearing, but their position underscores the ongoing tension between insurers and patients facing life‑threatening illnesses. The case highlights the broader challenge of securing coverage for high‑cost, cutting‑edge treatments under current health‑insurance policies.
As the legal battle continues, the Langesfeld family hopes the court will reaffirm the earlier ruling, ensuring Pablo receives the medication his doctors deem essential for his fight against cancer.
Original reporting: NBC6 Miami — read the source article.
